Literature DB >> 26198441

Endothelium-enriched microRNAs as diagnostic biomarkers for cardiac allograft vasculopathy.

Neha Singh1, Ward Heggermont2, Steffen Fieuws3, Johan Vanhaecke4, Johan Van Cleemput4, Bart De Geest5.   

Abstract

BACKGROUND: Cardiac allograft vasculopathy (CAV) is a limiting factor for the long-term survival of heart transplant recipients. Clinical decisions and care may be improved by the development of prediction models based on circulating biomarkers. The endothelium may play a central pathogenetic role in the development of CAV. We evaluated the hypothesis that endothelium-enriched microRNAs (miRNAs) discriminate between patients with and without CAV.
METHODS: This cross-sectional study recruited 52 patients undergoing coronary angiography between 5 and 15 years after heart transplantation. Circulating levels of endothelium-enriched miRNAs (miR-21-5p, miR-92a-3p, miR-92a-1-5p, miR-126-3p, and miR-126-5p) were quantified by real-time reverse transcription polymerase chain reaction. The discriminative ability of logistic regression models was evaluated using the concordance (C) statistic.
RESULTS: Median plasma levels of miR-210-5p, miR-92a-3p, miR-126-3p, and miR-126-5p were 1.82-fold (p = not significant), 1.87-fold (p < 0.05), 1.94-fold (p = 0.074), and 1.59-fold (p = 0.060) higher in patients with CAV than in patients without CAV. Recipient age (C statistic = 0.689; 95% confidence interval [CI], 0.537-0.842), and levels of serum creatinine (C statistic = 0.703; 95% CI, 0.552-0.854), miR-92a-3p (C statistic = 0.682; 95% CI, 0.533-0.831), and miR-126-5p (C statistic = 0.655; 95% CI, 0.502-0.807) predicted CAV status in univariable models. In multivariable logistic regression models with recipient age and creatinine as covariates, miR-126-5p (chi-square = 4.37(1), p = 0.037), miR-92a-3p (chi-square = 6.01(1), p = 0.014), and the combination of miR-126-5p and miR-92a-3p (chi-square = 8.16(2), p = 0.017) added significant information. The model with age, creatinine, miR-126-5p, and miR-92a-3p as covariables conferred good discrimination between patients without and with CAV (C statistic = 0.800; 95% CI, 0.674-0.926).
CONCLUSIONS: Endothelium-enriched miRNAs have diagnostic ability for CAV beyond clinical predictors.
Copyright © 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac allograft vasculopathy; endothelium; heart transplantation; microRNA; prediction model

Mesh:

Substances:

Year:  2015        PMID: 26198441     DOI: 10.1016/j.healun.2015.06.008

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

Review 1.  Blood-based immunological monitoring after heart transplant. Current status and future prospects.

Authors:  Jignesh K Patel
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-03-02

2.  Protective Role of miR-34c in Hypoxia by Activating Autophagy through BCL2 Repression.

Authors:  Soyoung Kim; Jaeseok Han; Young-Ho Ahn; Chang Hoon Ha; Jung Jin Hwang; Sang-Eun Lee; Jae-Joong Kim; Nayoung Kim
Journal:  Mol Cells       Date:  2022-06-30       Impact factor: 4.250

3.  Protective role of small extracellular vesicles derived from HUVECs treated with AGEs in diabetic vascular calcification.

Authors:  Bei Guo; Su-Kang Shan; Feng Xu; Xiao Lin; Fu-Xing-Zi Li; Yi Wang; Qiu-Shuang Xu; Ming-Hui Zheng; Li-Min Lei; Chang-Chun Li; Zhi-Ang Zhou; Muhammad Hasnain Ehsan Ullah; Feng Wu; Xiao-Bo Liao; Ling-Qing Yuan
Journal:  J Nanobiotechnology       Date:  2022-07-16       Impact factor: 9.429

Review 4.  MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential.

Authors:  Palak Shah; Michael R Bristow; J David Port
Journal:  Curr Heart Fail Rep       Date:  2017-12

5.  Single Donor Infusion of S-Nitroso-Human-Serum-Albumin Attenuates Cardiac Isograft Fibrosis and Preserves Myocardial Micro-RNA-126-3p in a Murine Heterotopic Heart Transplant Model.

Authors:  Anne-Kristin Schaefer; Attila Kiss; André Oszwald; Felix Nagel; Eylem Acar; Arezu Aliabadi-Zuckermann; Matthias Hackl; Andreas Zuckermann; Renate Kain; Andrzej Jakubowski; Peter Ferdinandy; Seth Hallström; Bruno K Podesser
Journal:  Transpl Int       Date:  2022-04-13       Impact factor: 3.842

Review 6.  Promising Directions in Atherosclerosis Treatment Based on Epigenetic Regulation Using MicroRNAs and Long Noncoding RNAs.

Authors:  Daria Skuratovskaia; Maria Vulf; Aleksandra Komar; Elena Kirienkova; Larisa Litvinova
Journal:  Biomolecules       Date:  2019-06-11

7.  Dissecting miRNA-Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine.

Authors:  Fani Chatzopoulou; Konstantinos A Kyritsis; Christos I Papagiannopoulos; Eleftheria Galatou; Nikolaos Mittas; Nikoleta F Theodoroula; Andreas S Papazoglou; Efstratios Karagiannidis; Maria Chatzidimitriou; Anna Papa; Georgios Sianos; Lefteris Angelis; Dimitrios Chatzidimitriou; Ioannis S Vizirianakis
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

Review 8.  Cardiac allograft vasculopathy: current review and future research directions.

Authors:  Jordan S Pober; Sharon Chih; Jon Kobashigawa; Joren C Madsen; George Tellides
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

9.  Low MicroRNA-126 Levels in Right Ventricular Endomyocardial Biopsies Coincide With Cardiac Allograft Vasculopathy in Heart Transplant Patients.

Authors:  Ward A Heggermont; Leen Delrue; Karen Dierickx; Riet Dierckx; Sofie Verstreken; Marc Goethals; Jozef Bartunek; Marc Vanderheyden
Journal:  Transplant Direct       Date:  2020-04-15

Review 10.  Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases.

Authors:  Kyriacos Felekkis; Christos Papaneophytou
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.